Gemma’s Story 
Given 3 Months to Live

Lucky to be alive 
(Magazine article)

You Tube Video of Gemma

Understanding the 
Recovery  Process

Common Aliments

Read chapter 1 of my ebook for FREE 


FAQ About Gemma Consultations Fees Contact Us Recovery Process



Temple Way, Birmingham,B69 3JR
Tel: 0121 557 0226

Breast Cancer

A landmark paper on homeopathy and cancer appeared in the February 2010 issue of the International Journal of Oncology. Scientists at the University of Texas M.D. Anderson Cancer Center (MDA), led by Dr. Moshe Frenkel, have demonstrated the beneficial effects of homeopathic medicines on breast cancer cells. Four ultra-dilute remedies were used in the study i.e. Carcinosin, Phytolacca, Conium and Thuja.

According to the researchers: "The remedies exerted preferential cytotoxic effects against the two breast cancer cell lines, causing cell cycle delay/arrest and apoptosis".

It was particularly interesting that the cell-killing effects of two of the remedies investigated in the study i.e. Carcinosin and Phytolacca, appeared similar to the activity of paclitaxel (Taxol), the most commonly used chemotherapeutic drug for breast cancer, without the toxic effect on the normal cells. The findings demonstrated biological activity of these products when presented at ultra-diluted doses.

According to Dr. Frenkel: "This is the first scientific study that investigated the effect of homeopathic remedies on breast cancer cells." Dr. Frenkel referred to its significance as an "exciting possibility" because of the "therapeutic opportunity for preferentially eliminating breast cancer cells with minimal damage to the surrounding normal mammary tissue by using homeopathic remedies."

Background to the study:

In 1999 the US National Cancer Institute (NCI) in the United States evaluated a cancer treatment protocol developed at the P. Banerji Homeopathic Research Foundation (PBHRF) in Kolkata, India. The ‘Banerji protocol’ used specific ultra-diluted natural substances to treat patients with different cancers. The NCI reviewed 10 patients treated on the Banerji protocol. In four of the cases with lung and esophageal cancers, the NCI confirmed partial responses. All patients reviewed had appropriate pathology and imaging studies to confirm diagnosis and response. The patients only received the remedies prescribed at the PBHRF clinic and did not receive any additional conventional treatment, such as surgery, radiation, or chemotherapy. After rigorous evaluation, the NCI concluded that there was sufficient evidence of efficacy to warrant further research of the Banerji protocol. As a result of growing interest in Banerji protocol remedies among patients at the M.D. Anderson Cancer Center of the University of Texas, most of whom have advanced breast cancer, a team of researchers decided to evaluate the in-vitro effect of those remedies and the landmark paper in the International Journal of Oncology was the result.

Best wishes,


Dr. Alan BSc, MA, MBA, PhD, CBiol, FBS